<博士論文>
原発性肺腺癌における PD-L1 タンパク発現の臨床的意義
作成者 | |
---|---|
論文調査委員 | |
本文言語 | |
学位授与年度 | |
学位授与大学 | |
学位 | |
学位種別 | |
出版タイプ | |
アクセス権 | |
関連DOI | |
概要 | INTRODUCTION: The clinicopathological features of carcinomas expressing programmed death ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in the EGFR gene, in lu...ng adenocarcinoma are not clearly understood. Here, we examined PD-L1 protein expression in surgically resected primary lung adenocarcinoma and the association of PD-L1 protein expression with clinicopathological features, EGFR mutation status, and patient outcomes. METHODS:The expression of PD-L1 protein in 417 surgically resected primary lung adenocarcinomas was evaluated by immunohistochemical analysis. The cutoff value for defining PD-L1 positivity was determined according to the histogram of proportions of PD-L1-positive cancer cells. RESULTS:Samples from 85 patients (20.4%) and 144 patients (34.5%) were positive for PD-L1 protein expression according to 5% and 1% PD-L1 cutoff values, respectively. Fisher's exact tests showed that PD-L1 positivity was significantly associated with male sex, smoking, higher tumor grade, advanced T status, advanced N status, advanced stage, the presence of pleural and vessel invasions, micropapillary or solid predominant histological subtypes, and wild-type EGFR. Univariate and multivariate survival analyses revealed that patients with PD-L1 positivity had poorer prognoses than those without PD-L1 protein expression at the 1% cutoff value (disease-free survival p < 0.0001, overall survival p < 0.0001). CONCLUSIONS:PD-L1 protein expression was significantly higher in smoking-associated adenocarcinoma and in EGFR mutation-negative adenocarcinoma. PD-L1 protein expression was associated with poor survival in patients with lung adenocarcinoma. The PD-L1/programmed cell death 1 pathway may contribute to the progression of smoking-associated tumors in lung adenocarcinoma.続きを見る |
本文ファイル
ファイル | ファイルタイプ | サイズ | 閲覧回数 | 説明 |
---|---|---|---|---|
med2953 | 2.15 MB | 451 | 本文 | |
med2953_abstract | 91.9 KB | 237 | 要旨 | |
med2953_summary | 91.9 KB | 416 | 要約 | |
med2953_review | 175 KB | 305 | 審査結果要旨 |
詳細
レコードID | |
---|---|
査読有無 | |
権利関係 | |
関連PubMed ID | |
報告番号 | |
学位記番号 | |
授与日(学位/助成/特許) | |
受理日 | |
部局 | |
登録日 | 2017.05.12 |
更新日 | 2020.10.09 |